Davis Polk advised Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC as underwriters in connection with an SEC-registered offering by Medicis Pharmaceutical Corporation (Medicis) of an aggregate principal amount of $500 million of 1.375% convertible senior notes due 2017, which included $50 million aggregate principal of notes from the full exercise of the underwriters’ over-allotment option. In addition, Davis Polk advised Deutsche Bank AG, London Branch and JPMorgan Chase Bank, National Association as counterparties to convertible note hedge and warrant transactions with Medicis in connection with the convertible senior notes offering.
Medicis is a leading independent specialty pharmaceutical company focusing primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the U.S. and Canada of products for the treatment of dermatological and aesthetic conditions.
The Davis Polk capital markets team included partner John B. Meade, associates Wendi Hoeben and Denise Yablonovich, and law clerks Sheldon Laing and Marcus Hintze. The Davis Polk equity derivatives team included partner Ray Ibrahim and associates Jonathan Armstrong, Noah L. Wynkoop, Charles L. Nail and Carol Pang. Partner Frank J. Azzopardi and associates David R. Bauer and Bruce Rose-Innes provided intellectual property advice. Partner Lucy W. Farr and associate Kerry S. Price provided tax advice. The environmental team included counsel Loyti Cheng and associate Catharine Thorpe. Kristyn M. Dunleavy was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York office.
